These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30957573)

  • 1. Updates on thrombotic events associated with multiple myeloma.
    Fotiou D; Gavriatopoulou M; Ntanasis-Stathopoulos I; Migkou M; Dimopoulos MA; Terpos E
    Expert Rev Hematol; 2019 May; 12(5):355-365. PubMed ID: 30957573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations.
    Swan D; Rocci A; Bradbury C; Thachil J
    Br J Haematol; 2018 Nov; 183(4):538-556. PubMed ID: 30450656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloma and thrombotic complications.
    Tzoran I; Brenner B; Hoffman R
    Minerva Med; 2013 Apr; 104(2):155-60. PubMed ID: 23514991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the venous thrombotic issues associated with multiple myeloma.
    Fotiou D; Gerotziafas G; Kastritis E; Dimopoulos MA; Terpos E
    Expert Rev Hematol; 2016 Jul; 9(7):695-706. PubMed ID: 27232265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboprophylaxis in multiple myeloma.
    Thalambedu N; Al Hadidi S
    Leuk Lymphoma; 2022 Dec; 63(12):2807-2815. PubMed ID: 35759648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?
    Lapietra G; Serrao A; Fazio F; Petrucci MT; Chistolini A
    J Thromb Thrombolysis; 2021 Aug; 52(2):584-589. PubMed ID: 33417149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools.
    Fotiou D; Gavriatopoulou M; Terpos E
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31940972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation.
    Baker HA; Brown AR; Mahnken JD; Shireman TI; Webb CE; Lipe BC
    Cancer Med; 2019 Jan; 8(1):455-462. PubMed ID: 30585435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients.
    Song AB; Rosovsky RP; Connors JM; Al-Samkari H
    Vasc Health Risk Manag; 2019; 15():175-186. PubMed ID: 31417269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the risk of venous thromboembolism in multiple myeloma.
    Sanfilippo KM
    Thromb Res; 2020 Jul; 191 Suppl 1():S74-S78. PubMed ID: 32736783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality Improvement at an Academic Cancer Center: Venous Thromboembolism Prophylaxis in Patients With Multiple Myeloma.
    Baz R; Furman R; Simondsen K; Stone C
    Cancer Control; 2020; 27(2):1073274820930204. PubMed ID: 32551873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system.
    Parnes A; Leblebjian H; Hamilton J; Smith S; Laubach J; Berliner N
    J Oncol Pharm Pract; 2022 Mar; 28(2):421-424. PubMed ID: 33611974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
    Sanfilippo KM; Luo S; Wang TF; Fiala M; Schoen M; Wildes TM; Mikhael J; Kuderer NM; Calverley DC; Keller J; Thomas T; Carson KR; Gage BF
    Am J Hematol; 2019 Nov; 94(11):1176-1184. PubMed ID: 31379000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
    Al-Ani F; Bermejo JM; Mateos MV; Louzada M
    Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group.
    Frenzel L; Decaux O; Macro M; Belhadj-Merzoug K; Manier S; Touzeau C; Leleu X; Frère C; Lecompte T; Perrot A; Avet-Loiseau H; Moreau P; Chalayer E
    Thromb Res; 2024 Jan; 233():153-164. PubMed ID: 38064842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study.
    Leclerc V; Karlin L; Herledan C; Marchal L; Baudouin A; Gouraud A; Caffin AG; Larbre V; Lazareth A; Bachy E; Salles G; Ghesquières H; Rioufol C; Ranchon F
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):975-984. PubMed ID: 34143239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
    Abdel-Razeq H; Finianos A; Taher AT
    Expert Rev Hematol; 2018 Jun; 11(6):487-494. PubMed ID: 29791257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of cancer-associated venous thromboembolism - a case-based practical approach.
    Voigtlaender M; Langer F
    Vasa; 2018 Feb; 47(2):77-89. PubMed ID: 29325495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
    Ay C; Pabinger I; Cohen AT
    Thromb Haemost; 2017 Jan; 117(2):219-230. PubMed ID: 27882374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.